Marker Therapeutics Inc (MRKR)

[Phantom Lord]

I'm not talking about long term data. We are supposed to get interim data from the phase II trials, TPIV200 & Durvalumab combo trial (NCT02764333) and the TPIV200 trial in TNBC (NCT02593227).

The below is copied from the last 10Q HERE. (Condensed to show the dates).

Enrollment Completed: Phase II TPIV200 Trial in Triple-Negative Breast Cancer

"The study completed enrollment at the end of 2017, with interim data expected in mid-2018."

Enrolling Patients: Phase II Trial at Memorial Sloan Kettering of TPIV200 [& Durvalumab] in Platinum-Resistant Ovarian Cancer

"Currently more than 50% of patients have been enrolled. An interim analysis is planned in the second half of 2018."


I think they continue these currently active trials but don't put a whole lot of effort into furthering the vaccines via more combination trials. While I believe that the vaccines still have potential the company is clearly focused on the cell therapy. Too many peptide vaccines have failed to the point no one applies any value to them until they have mature data. While I don't think it will happen it wouldn't surprise me to see us completely abandon the vaccines at some point. Luckily there has been a lot of funding from the DoD.

I think the problem right now with the valuation is just the exchange of shares happening. There have been some pretty large sales going through that are causing some decent share price drops which only causes uncertainty for people on the sidelines. The small float doesn't help this. I believe some of the smaller shareholders in the last offering might be liquidating some or all of their positions. Due to my resentment for them I'm going to assume it's partly Brio's and Iroquois' fault, lol. Either way once this settles down we should start to see the share price more in line with what the proper valuation should be. It's definitely more than ~$300M. I'm hoping for somewhere between $15 - $20 a share by the beginning of Q2 next year. That's provided none of the warrants are exercised. Either way, a lot higher than where we are now.